ProMIS Neurosciences (PMN) Payables (2021 - 2026)
ProMIS Neurosciences' (PMN) quarterly Payables came in at $1.7 million in Q1 2026, up 43.05% YoY from $1.2 million in Q1 2025, and down 32.5% on a QoQ basis from $2.5 million in Q4 2025.
ProMIS Neurosciences (PMN) Payables (2021 - 2026) Analysis & Trends
ProMIS Neurosciences (PMN) has 6 years of Payables data on file, last reported at $1.7 million in Q1 2026.
- Quarterly Payables rose 43.05% year-over-year to $1.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.7 million (up 43.05% YoY) and the FY2025 annual result came in at $2.5 million, up 46.39% from the prior year.
- Payables eased to $1.7 million in Q1 2026, from $2.5 million in the prior quarter.
- In the past five years, Payables ranged from a high of $8.4 million in Q3 2023 to a low of $888015.0 in Q2 2022.
- A 5-year average of $3.8 million and a median of $2.7 million in 2025 frame the typical range for Payables.
- Annual changes were most pronounced in 2023 — Payables soared 796.73% — and 2024, when it tumbled 81.28%.
- Tracing PMN's Payables over 5 years: stood at $3.0 million in 2022, then jumped by 163.6% to $7.8 million in 2023, then slumped by 77.85% to $1.7 million in 2024, then surged by 46.39% to $2.5 million in 2025, then sank by 32.5% to $1.7 million in 2026.
- The last three Payables figures came in at $1.7 million (Q1 2026), $2.5 million (Q4 2025), and $4.2 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.83 Bn | 130.98 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.79 Bn | 77.79 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 64.95 Bn | 59.77 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 58.59 Bn | 53.46 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 41.93 Bn | 36.83 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 31.52 Bn | 28.21 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 27.98 Bn | 9.58 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 35.57 Mn |
| 10 | ProMIS Neurosciences | 135.44 Mn | 81.98 Mn | - | 1.79 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.79 Mn |
| Mar 31, 2026 | 1.72 Mn |
| Dec 31, 2025 | 2.54 Mn |
| Sep 30, 2025 | 4.21 Mn |
| Jun 30, 2025 | 2.78 Mn |
| Mar 31, 2025 | 1.20 Mn |
| Dec 31, 2024 | 1.74 Mn |
| Sep 30, 2024 | 1.58 Mn |
| Jun 30, 2024 | 2.02 Mn |
| Mar 31, 2024 | 5.90 Mn |
| Dec 31, 2023 | 7.84 Mn |
| Sep 30, 2023 | 8.41 Mn |
| Jun 30, 2023 | 7.96 Mn |
| Mar 31, 2023 | 6.99 Mn |
| Dec 31, 2022 | 2.98 Mn |
| Sep 30, 2022 | 1.79 Mn |
| Jun 30, 2022 | 888,015.00 |
| Dec 31, 2021 | 408,981.00 |